CTLA4 and non-small cell lung carcinoma: Ipilimumab is a fully human IgG-1 mAb directed against CTLA-4 that showed promising results when combined with nivolumab in metastatic melanoma [19], opening the way for its use in other malignancies, including advanced NSCLC.